Key Takeaways
- Shifting Focus: Despite a research boom (nearly 4,000 papers/year), 50% of studies still focus solely on two molecules—CBD and THC.
- New Heroes: Minor cannabinoids like CBC (cannabichromene) and CBN (cannabinol) are showing powerful potential in neuroprotection and pain relief, despite making up less than 2% of scientific literature.
- Innovation: Scientists are exploring exotic compounds, such as molecules from snail venom, that mimic endocannabinoids to restore memory.
- “Entourage” Critique: Researchers are calling to replace the term “entourage effect” with more precise pharmacological definitions of synergy.
Introduction: The “Two-Molecule” Problem
California legalized medical cannabis nearly 30 years ago, sparking a global wave of reform. However, scientific progress has long lagged behind public enthusiasm. Only recently have we seen an explosion in publications regarding the therapeutic potential of cannabinoids: while only about 100 articles were published annually in the 90s, that number soared to 3,944 by 2022.
But there is a catch: science is stuck on the industry’s “stars.” Over 50% of all research is dedicated to cannabidiol (CBD)and tetrahydrocannabinol (THC) (we’ve summarized the evidence on cannabidiol in our complete guide). Meanwhile, Cannabis sativa contains over 150 other active phytocannabinoids that remain largely in the shadows.
The Biomedicines (2025) Special Issue, titled “Therapeutic Potential for Cannabis and Cannabinoids 2.0,” aims to correct this imbalance by ushering in an era of deep dives into these rare compounds.
Beyond THC: The Hidden Potential of Minor Cannabinoids
A new wave of research, which Special Issue editor Wesley Raup-Konsavage calls “Cannabinoids 2.0,” focuses on molecules that occupy less than 2% of the scientific literature—CBG, CBC, and CBN.
1. CBC (Cannabichromene) — A New Analgesic
Studies indicate that CBC possesses a unique receptor profile distinct from other phytocannabinoids.
- How it works: AI modeling predicted that CBC could work in synergy with other minor cannabinoids.
- The Result: CBC has demonstrated efficacy in various pain models, paving the way for new, non-addictive painkillers. Understanding the genetic markers that influence cannabinoid production could be key to stabilizing the supply of these rare compounds.
2. CBN (Cannabinol) — Protecting Neurons
For a long time, CBN was considered merely a degradation product of THC. A new study by Trainito et al. has upended this view.
- The Discovery: CBN is non-toxic to neuronal cells and modulates genes responsible for the cell cycle.
- The Benefit: This suggests CBN has neuroprotective properties—the ability to shield brain cells from damage.
3. Snail Venom and Memory
One of the most unexpected studies came from Guilherme et al., who investigated oleoyl serotonin, a compound isolated from the venom of the Stephanoconus snail.
- Mechanism: Structurally, this molecule resembles our own endocannabinoids. It blocks CB2 receptors and inhibits CB1.
- Effect: The substance was able to reverse memory deficits in mice caused by synthetic cannabinoids.
Practical Applications: Pain, Diabetes, and Epilepsy
The Biomedicines Special Issue offers concrete data on treating severe conditions.
Neuropathy and Diabetes
A combination of CBD and the terpene beta-caryophyllene showed excellent results in rats with diabetic neuropathy. This “cocktail” reduced hyperalgesia (increased sensitivity to pain) by boosting antioxidant and anti-inflammatory activity.
Another study compared CBD and CBG for chemotherapy-induced neuropathy (oxaliplatin). Interestingly, their combination produced different effects depending on the dose: sometimes they enhanced each other (synergy), and other times they interfered (sub-additivity). This highlights the need for further research into the therapeutic potential of CBG to optimize these dosing regimens.
Epilepsy
Even low doses of CBD can suppress excessive glutamate release (a neurotransmitter that triggers seizures) in tissues from patients with drug-resistant epilepsy. However, scientists discovered that some patient synapses remain resistant to treatment, though the reason remains unclear.
Statistics: The Surge in Scientific Interest
To understand the scale of these changes, look at the trajectory of publications for the search term “cannabis” in PubMed. We are witnessing exponential growth in scientific interest.
Table 1. Cannabis Research Publication Trends
| Period | Avg. Articles/Year | Key Events |
| 1980–2000 | ~114 | Era of stagnation and prohibition. |
| 2004 | Growth | Noticeable increase begins post-California legalization (1996). |
| 2022 | 3944 | Peak publications. Dominance of CBD and THC. |
| 2023–2024 | ~3750 | Stabilization at high levels. |
Note: Despite the growth, in 2022 CBD accounted for 28.7% of papers and THC for 22.6%, while CBG, CBC, and CBN combined made up less than 4%.
Risks and Industry Challenges
Not all news is positive. A review of medical cannabis use in older adults (mean age 79) showed that 36.1% of participants experienced adverse events. The most common was dizziness, which is critically dangerous for seniors due to fall risks.
Furthermore, scientists are questioning the marketing term “entourage effect”. A review by Christensen et al. suggests abandoning this vague concept in favor of precise terms: pharmacokinetic modulation or bioenhancement. Literature on the “entourage effect” is often anecdotal and inconsistent.
As the industry matures, consistency becomes paramount. Just as we study how light intensity affects yield in cultivation, we must apply the same rigor to understanding pharmacological variability in the final product
FAQ
It represents a shift in research focus from the two main cannabinoids (THC and CBD) to “minor” or rare compounds like CBG, CBC, and CBN, as well as the study of terpenes and their synergy.
Studies show that cannabis use does not impair daily functioning in older adults, but more than a third of patients report adverse events, primarily dizziness. Strict medical supervision is required.
Yes, animal studies indicate that CBG (cannabigerol) is effective for neuropathic pain and may reduce opioid withdrawal symptoms.
CBC (cannabichromene) is a phytocannabinoid that has shown analgesic effects in multiple pain models. AI modeling predicts it targets a unique set of receptors distinct from THC or CBD.